Genotyping for drug-metabolizing enzymes - Does the promise meet the reality?

Pharmacogenomics

Volumn 5, Issue 8, 2004, Pages 1033-1036

  Gardiner, Sharon J ^a   Begg, Evan J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; AZATHIOPRINE; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; MERCAPTOPURINE; MESALAZINE; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; THIOPURINE METHYLTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

AREA UNDER THE CURVE; BLEEDING; BONE MARROW SUPPRESSION; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; ENTERITIS; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPONATREMIA; HYPOTENSION; PHARMACOGENETICS; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 11044231651     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.8.1033     Document Type: Conference Paper

References (7)

1. Hammer W, Sjoqvist F: Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine like compounds. Life Sci. 6(17), 1895-1903 (1967).
2. Dalén P, Dahl M-L, Bernal Ruiz ML, Nordin J, Bertilsson L: 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63(4), 444-452 (1998).
3. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2(3), 191-196 (2002).
4. Stedman CAM, Begg EJ, Kennedy MA, Roberts R, Wilkinson TJ: Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum. Psychopharmacol. 17(4), 187-190 (2002).
5. Tucker G: Pharmacogenetics - expectations and reality. Br. Med. J. 329, 4-6 (2004).
6. Aithal GP, Day CP, Kesteven PJL, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
7. Kamali F, Khan TI, King BP et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75(3), 204-212 (2004).